GLP-1/glucagon receptor co-agonism for treatment of obesity.
about
Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.In Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties.MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyPathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic ApproachesNo Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First CenturyFuture Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
P2860
GLP-1/glucagon receptor co-agonism for treatment of obesity.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@en
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@nl
type
label
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@en
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@nl
prefLabel
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@en
GLP-1/glucagon receptor co-agonism for treatment of obesity.
@nl
P2093
P2860
P1433
P1476
GLP-1/glucagon receptor co-agonism for treatment of obesity
@en
P2093
Matthias H Tschöp
Miguel A Sánchez-Garrido
Richard D DiMarchi
Sara J Brandt
Timo D Müller
P2860
P2888
P304
P356
10.1007/S00125-017-4354-8
P577
2017-07-21T00:00:00Z